Inmedix has discovered & is commercializing novel diagnostics & therapeutics to improve the lives of patients worldwide.
Inmedix commercializes its ANS Neuroscan diagnostic. Proof-of-concept study shows strong results.
Inmedix launches subsidiary, Inmedix UK Ltd, to initiate health outcomes research in the NHS single payer system.
Inmedix welcomes Michael Weinblatt MD to its Scientific Advisory Board. Dr. Weinblatt is the John R. and Eileen K. Riedman Professor of Medicine at Harvard Medical School and the R. Bruce and Joan M. Mickey Distinguished Chair in Rheumatology at the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital.